Connect with the future of healthcare
Imagine a world where natural, personalized “spare parts” could be used to replace damaged tissues or organs, restoring health and vitality to patients with severe diseases. These custom-made biological solutions would not only fit perfectly, but also integrate naturally with the body, reducing the risk of rejection and complications — just like replacing a part in a machine, but with the elegance and precision of nature itself.
Premarket/clinical phase
29.708.960€
2027
Personalized medicine
2.3%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
VERIGRAFT is pioneering personalized tissue therapies that act like custom-made “spare parts” for the human body, revolutionizing treatment for vascular disease.
By transforming donated tissues to match each patient’s biology, VERIGRAFT’s fully natural, tissue-engineered grafts eliminate the need for immunosuppression and reduce risks of rejection and infection — offering life-changing solutions to patients with severe and debilitating conditions for the first time.
VERIGRAFT’s first personalized tissue therapy for the treatment of severe chronic venous insufficiency is in clinical trials. Phase I/II trials demonstrate the safety and efficacy.
The first-of-a-kind clinical trials are performed at multiple university hospitals in Spain. P-TEV grafts with functional venous valves can restore normal blood flow in the legs of patients with chronic venous insufficiency. In this way the underlying cause of the disease is treated and symptoms such as painful swelling and long term ulcers are improved.
With promising clinical trial results and a clear regulatory strategy, the company is on track for market approval in Europe and the USA by 2027, while planning a strategic exit in 2-3 years.
VERIGRAFT’s development pipeline comprises regenerative therapies for several major disease indications.
The company’s innovations are protected by 82 strong patents throughout the world.
VERIGRAFT’s solutions have a vast market potential across multiple important medical fields:
With cutting-edge facilities in Gothenburg, Sweden, and a global team of collaborators and advisors, VERIGRAFT is set to reshape the future of regenerative medicine.
VERIGRAFT’s strategic positioning, breakthrough technology, and strong stakeholder support make it a key player in tissue therapies and regenerative medicine. VERIGRAFT is ready to meet critical unmet needs and capture a major share of the global tissue therapy market.
Imagine the transformative impact when surgeons can transplant fully natural, personalized replacement tissues to treat seriously ill patients.
Chronic Venous Insufficiency (CVI) is a widespread condition with limited effective treatments. Verigraft's innovative decellularization technology allows donated tissue to match the recipient's tissue, eliminating rejection and the need for immunosuppression. Their Personalized Tissue-Engineered Veins (P-TEV) are in Phase I/II clinical trials, showing promising results.
Verigraft's technology is backed by numerous peer-reviewed studies and has potential applications in personalized arteries, nerves, and heart valves. The CVI market is a billion-dollar opportunity with significant unmet needs. Verigraft's strong IP portfolio, with 82 patents protecting them until 2039, and a strategic business plan for global commercialization make them a compelling investment. Market entry is anticipated by 2027, with a high likelihood of success despite some competition.
Although the project shows promising early results, it is still in its middle stages, requiring extensive and costly clinical trials. There is a risk that these trials may not demonstrate the expected efficacy, potentially hindering certification from regulatory bodies such as the FDA.
Additionally, market adoption can be slow as healthcare providers may be reluctant to switch from established treatments, and competing solutions might reach the market sooner or prove more effective.
Already have an account? Please login here .
